Plain-English translation of NCT06247605 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Small Cell Lung Carcinoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called AL8326 for people with advanced or recurrent small cell lung cancer who have already received at least two rounds of prior treatment. About half of participants will receive the new medication, and half will receive a placebo (a pill with no active medicine), taken once daily. The study will track how well this treatment works and how safe it is over up to 12 months.
Small cell lung cancer is an aggressive cancer, and many patients eventually stop responding to standard treatments. This medication is being tested to see if it can help people whose cancer has progressed despite earlier therapies.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take one pill by mouth each day for 28-day cycles, continuing for up to 12 months (about 13 cycles) or until your cancer progresses, you experience intolerable side effects, or you choose to stop. You will have regular clinic visits and imaging scans to measure how your cancer is responding. Half of participants will receive the active medication, and half will receive placebo—neither you nor your doctors will know which one you're getting during the trial.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China